We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Androgen receptor expression in male breast cancer predicts inferior outcome and poor response to tamoxifen treatment.
- Authors
Zhao Wenhui; Li Shuo; Tang Dabei; Piao Ying; Wang Zhipeng; Zhong Lei; He Xiaohui; Geng Jingshu; Song Hongtao; Zhang Qingyuan
- Abstract
Objective: Androgen receptor (AR) plays an important role in male breast cancer (MBC). Additionally, endocrine therapy is the most important treatment in oestrogen receptor (ER)-positive advanced breast cancer. This study was aimed to investigate the role of AR in MBC treatment and prognosis and to analyse the relationship between AR and the effect d of tamoxifen treatment in MBC patients. Methods: AR protein levels and other tumour characteristics (e.g. expression of ER (ESR1), PR (PGR), AR, HER2 (ERBB2) g and Ki-67 (MKI67)) in breast cancer tissue from 102 MBC patients were determined using immunohistochemical analysis. 1: Additionally, the relationship between AR status and clinicopathological features was analysed using the X²-test. Association with survival was initially analysed using the Kaplan-Meier method and the log-rank test, and Cox regression analysis was 1 used to adjust for other prognostic indicators. Results: High expression of AR was not correlated with T-stage, histological grade, HER2 status and the status of other sex c hormone receptors, but was associated with lymph node metastases (P=0.032). AR-positive patients showed significantly shorter 5-year overall survival (OS) rates (P=0.045) and 5-year disease-free survival (DFS) rates (P=0.026) than AR-negative patients. By contrast, for patients who received tamoxifen therapy, AR-negative patients showed a higher clinical benefit rate than AR-positive patients (P=0.025). Additionally, the median TTP and OS were significantly different (P=0.02 for TTP; P= 0.029 for OS). Conclusions: AR expression correlates strongly with both OS and DFS in patients with MBC. AR-positive patients can predict a poorer clinical outcome than AR-negative patients after adjuvant tamoxifen therapy.
- Subjects
BREAST cancer prognosis; ANDROGEN receptors; MEN'S health; TAMOXIFEN; HORMONE therapy; DRUG efficacy
- Publication
European Journal of Endocrinology, 2014, Vol 171, Issue 4, p527
- ISSN
0804-4643
- Publication type
Article
- DOI
10.1530/EJE-14-0278